NEW YORK, Oct. 8 — Rosetta Biosoftware, the new business unit of Rosetta Inpharmatics, which is a wholly owned subsidiary of Merck, and Agilent, the distributor of Rosetta software, said on Monday that GlaxoSmithKline is the first licensee of version 2.0 of the Rosetta Resolver Software Development Kit. The kit enables users of the Resolver gene expression data storage and analysis program to access the system's open application program interfaces in order to enhance and customize the product. According to Rosetta Biosoftware, users can incorporate their own error models and clustering algorithms via the system's open APIs. Error models are plugged in using Java technology, while clustering algorithms are incorporated using both C++ and Java.
Paul Matthews, project leader of gene expression bioinformatics at GlaxoSmithKline, which has been a customer of the Resolver software, said in a statement that his internal bioinformatics staff would make use of the open system to integrate it with Glaxo’s internally developed algorithms and bioinformatics tools.
Barney Saunders, vice president and general manager of Agilent's life sciences division, said, "Allowing customers access to the system's APIs is part of our commitment to provide tools that will most efficiently help our customers achieve their research goals."
Other Rosetta Resolver customers include Biogen, Bristol-Myers Squibb, and Merck. Merck acquired Rosetta Inpharmatics in May, and Rosetta spun off the Biosoftware business unit in September.